Spectra Optia Apheresis System Operator's Manual

Total Page：16

File Type：pdf, Size：1020Kb

SpectraOptiaOpsManual.book Page i Thursday, May 17, 2018 11:24 AM Spectra Optia® Apheresis System Operator’s Manual Part No. 777379-124 Reorder No. 703261-001 2018-04 SpectraOptiaOpsManual.book Page ii Thursday, May 17, 2018 11:24 AM ©2018 Terumo BCT, Inc. Terumo BCT is a registered trademark of Terumo Corporation. Seal Safe is a trademark of Terumo BCT, Inc. Spectra Optia is a registered trademark of Terumo BCT, Inc. This product may be covered by one or more patents or pending patent applications. See TERUMOBCT.COM/patents for details. Terumo BCT, Inc. 10811 W. Collins Avenue Lakewood, Colorado 80215 USA USA Phone: +1.877.339.4228 Phone: +1.303.231.4357 USA Fax: +1.866.715.6768 Fax: +1.303.542.5215 Terumo BCT Europe N.V. Ikaroslaan 41 1930 Zaventem, Belgium Phone: +32.2.715.05.90 Fax: +32.2.721.07.70 TERUMOBCT.COM SpectraOptiaOpsManual.book Page i Thursday, May 17, 2018 11:24 AM Contents Chapter 1: Preface . 1 About This Operator’s Manual . 2 Conventions Used in this Manual . 2 Numbered Steps . 2 Touch screen buttons . .2 Bullets . 2 Warnings, Cautions, and Notes . 2 Spectra Optia Apheresis System . 3 Intended Use . 3 Contraindications for Use . 3 Warnings and Cautions for Use . 3 Warnings for Use . 3 System warnings . .3 Service warnings . .4 Electrical warnings . .4 General procedural warnings . .4 Exchange procedure warnings . .6 Collection and depletion procedure warnings . .7 General tubing set warnings . .7 Accessory set warnings . .8 Fluid warnings . .8 Seal Safe system warnings . .8 Cautions for Use . 9 System cautions . .9 Service cautions . .10 General procedural cautions . .10 Collection and depletion procedure cautions . .11 General tubing set cautions . .12 Exchange Set cautions . .12 Collection Set cautions . .13 IDL Set cautions . .13 Fluid cautions . .13 Seal Safe system cautions . .14 Service Information . 15 Special Use of Additional Equipment and Devices During Apheresis Procedures . 15 Fluids Administered During Apheresis Procedures. 16 Saline Solution . 16 Anticoagulant . 16 ACD-A . .16 Hydroxyethyl Starch (HES) . .16 Spectra Optia Apheresis System Operator’s Manual i SpectraOptiaOpsManual.book Page ii Thursday, May 17, 2018 11:24 AM Contents Replacement Fluids . 16 Adverse Events of Apheresis Procedures . 17 Reactions to Blood Products Transfused During Procedures . 18 Disposal of Infectious and Non-Infectious Waste . 18 Return of Used Product . 18 Chapter 2: Introduction . 19 Spectra Optia System Description . 20 Spectra Optia System Components . 21 Front Panel . 23 Pumps . 23 Valves . 24 Sensors and detectors . 24 Return line air detector . ..

310

Copy Link

Recommended publications

Factors Affecting Mobilization of Peripheral Blood Progenitor Cells in Patients with Lymphoma’
Vol. 4, 311-316, February 1998 Clinical Cancer Research 311 Factors Affecting Mobilization of Peripheral Blood Progenitor Cells in Patients with Lymphoma’ Craig H. Moskowitz,2 Jill R. Glassman, (median, 13 versus 22 days; P 0.06). Patients who received 1l cycles of chemotherapy prior to PBPC mobilization David Wuest, Peter Maslak, Lilian Reich, tended to have delayed platelet recovery to >20,090/&l and Anthony Gucciardo, Nancy Coady-Lyons, to require more platelet transfusions than less extensively Andrew D. Zelenetz, and Stephen D. Nimer pretreated patients (median, 13.5 versus 23.5 days; P 0.15; Division of Hematologic Oncology, Department of Medicine median number of platelet transfusion episodes, 13 versus 9; [C. H. M., D. W., P. M., L. R., A. G., N. C-L., A. D. Z., S. D. N.] and P = 0.17). Department of Biostatistics [J. R. G.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021 These data suggest that current strategies to mobilize PBPCs may be suboptimal in patients who have received either stem cell-toxic chemotherapy or 11 cycles of chem- ABSTRACT otherapy prior to PBPC mobilization. Alternative ap- The objective of this study was to identify factors asso- proaches, such as ex vivo expansion or the use of other ciated with poor mobilization of peripheral blood progenitor growth factors in addition to G-CSE, may improve mobili- cells (PBPCs) or delayed platelet engraftment after high- zation of progenitor cells for PBPC transplantation. dose therapy and autologous stem cell transplantation in patients with lymphoma. INTRODUCTION Fifty-eight patients with Hodgkin’s disease or non- The use of high-dose chemoradiotherapy supported by Hodgkin’s lymphoma underwent PBPC transplantation as cryopreserved autologous hematopoietic progenitor cells is ef- the “best available therapy” at Memorial Sloan-Kettering fective in treating relapsed HD3 and NHL; a high complete Cancer Center (New York, NY) between 1993 and 1995.
[Show full text]
Blood Products for Neonatal Transfusion
Blood Products for Neonatal Transfusion Transfusion of Red Cell Products A. Red cells for topup transfusion Pedipaks should be used for all red cell topup transfusions in infants. One blood donation is split into four equal volumes (approximately 50ml) and 2 or 4 packs are reserved for an individual baby, depending on weight. The use of pedipaks enables us to minimise patient exposure to multiple donors. Pedipak specifications: • Available in O Positive and O Negative • CMV Negative • Leucocyte Depleted • Suitable for topup transfusion until expiry (42 days from collection) • Commence transfusion within 30 minutes of product receipt Pedipaks and complete transfusion within 4 hours of spiking pack. Volume to be infused: Routine – 15 20ml/Kg over 4 hours. Infants may require IV Frusemide (per RWH Drug Manual) half way through the transfusion – discuss with neonatologist/fellow Emergency – larger volume over shorter time period depending on condition of infant. B. Red cells for Exchange Transfusion Exchange transfusion is generally carried out for hyperbilirubinaemia and/or anaemia usually due to haemolytic disease of the newborn (HDN) or prematurity. ARCBS produces a red cell product specifically for neonatal exchange transfusion. This red cell product has the following specifications: • Group O Negative • Kell negative • CMV negative • Leucocyte Depleted • Fresh (<=5 days) • Known haematocrit (<0.6) • Irradiated at ARCBS (should be transfused within 24 hours of irradiation) • Commence transfusion within 30 minutes of product receipt and complete transfusion within 4 hours of spiking pack. Transfusion of Albumin Volume to be infused: • 4% Albumin as a volume expander. 10 – 20ml/Kg over 30 – 60 minutes • 20% Albumin used for hypoalbuminaemia.
[Show full text]
45 Part 606—Current Good Man- Ufacturing Practice
Food and Drug Administration, HHS Pt. 606 a presentation. The presiding officer ucts approved under § 601.91, the re- may, as a matter of discretion, permit strictions would no longer apply when questions to be submitted to the pre- FDA determines that safe use of the bi- siding officer for response by a person ological product can be ensured making a presentation. through appropriate labeling. FDA also (f) Judicial review. The Commissioner retains the discretion to remove spe- of Food and Drugs’ decision constitutes cific postapproval requirements upon final agency action from which the ap- review of a petition submitted by the plicant may petition for judicial re- sponsor in accordance with § 10.30 of view. Before requesting an order from a this chapter. court for a stay of action pending re- view, an applicant must first submit a PART 606—CURRENT GOOD MAN- petition for a stay of action under § 10.35 of this chapter. UFACTURING PRACTICE FOR BLOOD AND BLOOD COMPO- [67 FR 37996, May 31, 2002, as amended at 70 NENTS FR 14984, Mar. 24, 2005] § 601.93 Postmarketing safety report- Subpart A—General Provisions ing. Sec. Biological products approved under 606.3 Definitions. this subpart are subject to the post- marketing recordkeeping and safety Subpart B—Organization and Personnel reporting applicable to all approved bi- ological products. 606.20 Personnel. § 601.94 Promotional materials. Subpart C—Plant and Facilities For biological products being consid- 606.40 Facilities. ered for approval under this subpart, unless otherwise informed by the agen- Subpart D—Equipment cy, applicants must submit to the agency for consideration during the 606.60 Equipment.
[Show full text]
Clinical Pharmacology of Infusion Fluids
Clinical pharmacology of infusion fluids Robert G. Hahn Linköping University Post Print N.B.: When citing this work, cite the original article. Original Publication: Robert G. Hahn , Clinical pharmacology of infusion fluids, 2012, Acta Medica Lituanica, (19), 3. Licencee: Lithuanian Academy of Sciences http://www.lmaleidykla.lt/ojs/index.php/actamedicalituanica/index Postprint available at: Linköping University Electronic Press http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-91319 ACTA MEDICA LITUANICA. 2012. Vol. 19. No. 3. P. 210–212 © Lietuvos mokslų akademija, 2012 Clinical pharmacology of infusion fluids Robert G. Hahn Fluids are used for intravenous infusion during practically all surgeries, but several different compositions are available on the market. Södertälje Hospital, Crystalloid fluids comprise lactated or acetated Ringer solutions, nor- Södertälje, Sweden; mal saline, Plasma-Lyte, hypertonic saline, and glucose. They lack allergic Anaesthesia and properties but are prone to cause peripheral tissue oedema. Their turn- Intensive Care, over is governed by physiological factors such as dehydration and drug Linköping University, effects. Sweden Colloid fluids include hydroxyethyl starch, albumin, dextran, and gela- tin. These fluids have various degrees of allergic properties and do not promote peripheral oedema. Their half-life is usually about hours. Factors increasing the turnover rate are poorly known but might include inflam- matory states. Current debates include the widespread use of normal saline, which should be replaced by Ringer’s or Plasma-Lyte in most situations, and the kidney damage associated with the use of starch in septic patients. New studies show that hypertonic saline does not improve survival or neuro- logical damage in prehospital care.
[Show full text]
0985.03CC Non-Mobilized Donor Consent
Fred Hutchinson Cancer Research Center Consent to take part in a research study: 985.03CC – Non-Mobilized Donor Consent to Participate as a Donor of Non-Mobilized Peripheral Blood Mononuclear Cells for Laboratory Research and Process Development Studies. Principal Investigator: Derek Stirewalt, MD, Member, FHCRC, (206 667-5386) Investigators: Michael Linenberger, M.D., FACP Professor, Division of Hematology, UW, Robert & Phyllis Henigson Endowed Chair, Program Director, Hematology/Oncology Fellowship Medical Director, Apheresis and Cellular Therapy, SCCA, Member, FHCRC, Associate Professor of Medicine, UW, (206 667-5021); Laura Connelly Smith, Assistant Member, FHCRC, Assistant Professor, UW (206 606 -6938) Research Coordinator: Aubrey McMillan, (206) 667-3539 Emergency Phone (24 hours) UW Transplant unit 8NE: (206) 598-8902 UW Nocturnist on call provider (7:00 PM -7:00 AM): (206) 598-1062 Donor recruitment and participation: 206-667-5318 Important things to know about this study. You are invited to participate in a research study. The purpose of this research is to collect blood cells by a procedure called “leukapheresis”. Leukapheresis is a procedure that allows for a greater collection of peripheral blood cells than can be obtained by standard blood donation. Our purpose is to collect both small blood draws and larger samples of peripheral blood cells for laboratory research studies. This research may involve analysis of your genetic material called DNA and RNA. The studies may also examine other components of the cell like proteins. These analyses can be used to better understand cancer and other diseases. People who agree to join the study will be asked to attend 2 appointments over up to 30 days.
[Show full text]
Leukapheresis Protocol for Nonhuman Primates Weighing Less Than 10 Kg
Journal of the American Association for Laboratory Animal Science Vol 52, No 1 Copyright 2013 January 2013 by the American Association for Laboratory Animal Science Pages 70–77 Leukapheresis Protocol for Nonhuman Primates Weighing Less than 10 Kg Vimukthi Pathiraja, Abraham J Matar, Ashley Gusha, Christene A Huang, and Raimon Duran-Struuck* Leukapheresis is a common procedure for hematopoietic cell transplantation in adults. The main challenge in applying this procedure to human infants and small monkeys is the large extracorporeal blood volume (165 mL on average) necessary for priming the apheresis machine. This volume represents greater than 50% of the total circulating blood volume of a human neonate or small monkey. In this report, we document a safe leukapheresis protocol developed for rhesus macaques (3.9 to 8.7 kg). To avoid sensitizing donor animals undergoing leukapheresis to third-party blood products, autologous blood col- lected during the weeks prior to leukapheresis was used to volume-expand the same donor while priming the machine with saline on the day of leukapheresis. During the procedures, blood pressure was controlled by monitoring the inlet volume, and critical-care support was provided by the anesthesia team. Electrolytes and hemogram parameters were monitored intermit- tently. Overall, our research subjects underwent effective 4- to 6-h leukapheresis. A total of 9 leukapheresis procedures were performed, which yielded 1 × 109 to 6 × 109 peripheral blood mononuclear cells containing 1.1 to 5.1 × 106 CD34+ cells (assessed in 4 of 9 macaques) in a volume of 30 to 85 mL. All macaques showed decreases in Hct and platelet counts.
[Show full text]
Morphophonology of Magahi
International Journal of Science and Research (IJSR) ISSN: 2319-7064 SJIF (2019): 7.583 Morphophonology of Magahi Saloni Priya Jawaharlal Nehru University, SLL & CS, New Delhi, India Salonipriya17[at]gmail.com Abstract: Every languages has different types of word formation processes and each and every segment of morphology has a sound. The following paper is concerned with the sound changes or phonemic changes that occur during the word formation process in Magahi. Magahi is an Indo- Aryan Language spoken in eastern parts of Bihar and also in some parts of Jharkhand and West Bengal. The term Morphophonology refers to the interaction of word formation with the sound systems of a language. The paper finds out the phonetic rules interacting with the morphology of lexicons of Magahi. The observations shows that he most frequent morphophonological process are Sandhi, assimilation, Metathesis and Epenthesis. Whereas, the process of Dissimilation, Lenition and Fortition are very Uncommon in nature. Keywords: Morphology, Phonology, Sound Changes, Word formation process, Magahi, Words, Vowels, Consonants 1. Introduction 3.1 The Sources of Magahi Glossary Morphophonology refers to the interaction between Magahi has three kind of vocabulary sources; morphological and phonological or its phonetic processes. i) In the first category, it has those lexemes which has The aim of this paper is to give a detailed account on the been processed or influenced by Sanskrit, Prakrit, sound changes that take place in morphemes, when they Apbhransh, ect. Like, combine to form new words in the language. धमम> ध륍म> धरम, स셍म> सꥍ셍> सााँ셍 ii) In the second category, it has those words which are 2.
[Show full text]
Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL Or ALL
cells Article Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL Felix Korell 1,*, Sascha Laier 2, Sandra Sauer 1, Kaya Veelken 1, Hannah Hennemann 1, Maria-Luisa Schubert 1, Tim Sauer 1, Petra Pavel 2, Carsten Mueller-Tidow 1, Peter Dreger 1, Michael Schmitt 1 and Anita Schmitt 1 1 Department of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany; [email protected] (S.S.); [email protected] (K.V.); [email protected] (H.H.); [email protected] (M.-L.S.); [email protected] (T.S.); [email protected] (C.M.-T.); [email protected] (P.D.); [email protected] (M.S.); [email protected] (A.S.) 2 Institute of Clinical Transfusion Medicine and Cell Therapy (IKTZ), 89081 Heidelberg, Germany; [email protected] (S.L.); [email protected] (P.P.) * Correspondence: [email protected] Received: 9 April 2020; Accepted: 13 May 2020; Published: 15 May 2020 Abstract: Background: T lymphocyte collection through leukapheresis is an essential step for chimeric antigen receptor T (CAR-T) cell therapy. Timing of apheresis is challenging in heavily pretreated patients who suﬀer from rapid progressive disease and receive T cell impairing medication. Methods: A total of 75 unstimulated leukaphereses were analyzed including 45 aphereses in patients and 30 in healthy donors. Thereof, 41 adult patients with Non-Hodgkin’s lymphoma (85%) or acute lymphoblastic leukemia (15%) underwent leukapheresis for CAR-T cell production.
[Show full text]
A Typological Study of the Role of Syllable Contact in Romance Languages1
AUTHOR’S COPY | AUTORENEXEMPLAR It is all downhill from here: A typological study of the role of Syllable Contact in Romance languages1 CLÀUDIA PONS-MOLL Abstract The main purpose of this paper is to show that Syllable Contact is responsible for the application of an extensive set of processes drawn from Romance lan- guages and to explore the nature and effects of this constraint within Optimality Theory (OT) on the basis of the analysis of these phenomena. All the processes under examination entail a change in manner of articulation and are the fol- lowing: a) regressive manner assimilation in some varieties of Catalan and in Languedocian Occitan, b) alveolar fricative rhotacism in Majorcan Catalan, dialects of Sardinian and dialects of Galician and c) alveolar fricative gliding in Languedocian Occitan. The analysis of these processes leads to two important theoretical implica- tions. First, it provides strong empirical evidence that SYLLABLE CONTACT cannot be regarded as a single constraint which categorically bans coda-onset 1. Different versions of this paper have been presented at the XIII Col·loqui Internacional de Llengua i Literatura Catalanes (Girona, 2003), the 13th Manchester Phonology Meeting (Manchester, 2005), the Conference on Manner Alternations in Phonology (Berlin, 2005), the 10LabPhon (Paris, 2005) and the Cuny Phonology Forum (New York, 2008). For valu- able discussion on this paper, I am grateful to Eulàlia Bonet, Elisenda Campmany, Pere Gri- malt, Maria-Rosa Lloret, John Kingston, Joan Mascaró, John J. McCarthy, Anna Pineda, Laia Querol, Daniel Recasens, Donca Steriade, Francesc Torres-Tamant and to the audience of the aforementioned conferences (especially to Stuart Davis, Chiara Frigeni and Robert Ladd).
[Show full text]
Polymers for Blood Replacement Volume for 6 H, Is 90% Lost in 24 H and Is Said to Lack the Immunological Reactions of from Paul Calvert Dextran
108 Nature Vol. 280 12 July 1979 example, the J/tp at 3.1 GeV and the jet structure survives the final 'colour beneficial in shock cases. High molecular upsilon at 9.4 GeV. In these bound states washing' that creates only colourless weight dextran has anticoagulant activity the heavy quark-antiquark pair can decay hadrons out of the quark and the and it can be used for this purpose after hadronically only by annihilating into antiquark. As each of the gluons from surgery. Low molecular weight dextran is three gluons in much the same way that upsilon decay will on average carry an antigenic but there is no evidence for this positronium disintegrates into three energy of nearly 3 GeV, gluon jets can be with clinically-used dextran, although photons. The gluons of course have to expected there. The three gluons should allergic reactions occasionally occur. evolve into colourless hadrons later. The emerge symmetrically with 120° angles Various dextrans in the molecular weight glueball may lurk among such hadrons. between one another, and there is some range of 40,000-110,000 are used One interesting decay mode is when J/tp preliminary evidence for such events from depending on the balance of effect goes into an energetic photon plus hadrons. PLUTO (CERN Courier 19, 108; 1979). desired. Here the heavy quark-antiquark pair in the Another interesting possible configuration The Chinese work is from the Institute of J/tp annihilate into two gluons and a is one in which an energetic gluon dashes Organic Chemistry in Shanghai, one of the photon.
[Show full text]
The ABC's of Blood Components
The ABC’s of Blood Components Terry Downs, MT(ASCP)SBB Administrative Manager University of Michigan Hospitals Blood Bank and Transfusion Service Objectives Describe three additives used in blood components. List the indications for five blood components. Review whole blood donations versus apheresis collections. Whole Blood Donation Collection of one 450-500 mL of whole blood into a bag Bag then processed into components Additive solutions may be added Takes about 10 minutes to collect 500 mL Apheresis Collection of Blood Whole blood is separated into components during collection Desired component if removed Remaining components are returned to donor Centrifugal technique primarily used in US Allows for “double-red” or multiple plasma Apheresis platelets Granulocytes Collection and Storage Systems Different configurations based on intended processing method Manual processing Automated processing Platelet processing method Approved anticoagulants ACD-A ACD-B CPD CP2D CPDA-1 Contents of Anticoagulant-Preservative Solutions ACD-A CPD CP2D CPDA-1 Trisodium Citrate 22.0 g/L 26.3 g/L 26.3 g/L 26.3 g/L Citric Acid 8.0 g/L 3.27 g/L 3.27 g/L 3.27 g/L Monobasic Sodium Phosphate 0 2.22 g/L 2.22 g/L 2.22 g/L Dextrose 24.5 g/L 25.5 g/L 51.1 g/L 31.9 g/L Adenine 0 0 0 0.275 g/L Shelf Life (days) 21 21 21 35 ACD-A: Anticoagulant citrate-dextrose A CPD: Citrate-phosphate-dextrose CP2D: Citrate-phosphate-dextrose-dextrose CPDA-1: Citrate-phosphate-dextrose-adenine Additive Solutions Extend the shelf life to 42 days.
[Show full text]
IEC-International Electrotechnical Commission
Standards Manager Web Standards List IEC-International Electrotechnical Commission Id Number Title Year Organization Page 1 60034-2-3 Rotating electrical machines _ Part 2-3: Specific test methods for determining losses and efficiency of converter-fed AC 2020 IEC motors - Edition 1.0 2 60034-3 Rotating electrical machines _ Part 3: Specific requirements for synchronous generators driven by steam turbines or 2020 IEC combustion gas turbines and for synchronous compensators - Edition 7.0 3 60034-5 Rotating electrical machines _ Part 5: Degrees of protection provided by the integral design of rotating electrical machines 2020 IEC (IP code) _ Classification - Edition 5.0 4 60034-7 Rotating electrical machines _ Part 7: Classification of types of construction, mounting arrangements and terminal box 2020 IEC position (IM Code) - Edition 3.0 5 60034-11 Rotating electrical machines _ Part 11: Thermal protection - Edition 3.0 2020 IEC 6 60034-18-42 Rotating electrical machines _ Part 18-42: Partial discharge resistant electrical insulation systems (Type II) used in rotating 2020 IEC electrical machines fed from voltage converters _ Qualification tests - Edition 1.1; Consolidated Reprint 7 60045-1 Steam turbines _ Part 1: Specifications - Edition 2.0 2020 IEC 8 60050-113 NULL 2020 IEC AMD 2 9 60050-113 AMENDMENT 3 International Electrotechnical Vocabulary (IEV) _ Part 113: Physics for electrotechnology - Edition 1.0 2020 IEC AMD 3 10 60050-151 AMENDMENT 4 International Electrotechnical Vocabulary (IEV) _ Part 151: Electrical and magnetic devices
[Show full text]